Overview of This Study:
This study involved four major activities in estimating the current size of the electroceuticals market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Market Size Estimation:
Both top-down and bottom-up approaches were used to estimate and validate the electroceuticals market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
# The key players in the industry have been identified through extensive secondary research
# The revenues generated by leading players operating in the electroceuticals market have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Projected Revenue Surge:
The global electroceuticals/bioelectric medicine market is projected to reach USD 21.5 billion by 2026 from USD 16.8 billion in 2021, at a CAGR of 5.0%.
Download PDF [email protected]
Global Growth Driving Factors:
The rising geriatric population and subsequent growth in the prevalence of neurological & cardiovascular disorders drives growth in the electroceuticals market, rising government support & funding for neurological disorders, and the increasing investments and funding for research on CRM devices are among the other factors. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the electroceuticals market.
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
# In March 2021, Medtronic plc (Ireland) received US FDA approval for its Intellis Platform with Differential Target Multiplexed (DTM) programming to treat chronic intractable back and leg pain.
# In January 2021, Boston Scientific Corporation (US) received US FDA approval for its Vercise Genus Deep Brain Stimulation System.
# In January 2020, Medtronic plc (Ireland) acquired Stimgenics, LLC (US), a pioneer of DTM, a novel spinal cord stimulation therapy.
The hospitals, clinics, and ASCs segment accounted for the largest share of the electroceuticals market, by end user segment, in 2020
Based on end users, the electroceuticals market has been segmented into hospitals, clinics, and ASCs; and other end users. In 2020, the hospitals, clinics, and ASCs segment accounted for the largest share of the electroceuticals market. The improving healthcare infrastructure in developing countries is driving this segments growth.
North America is the largest regional market for electroceuticals market
The global electroceuticals market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the electroceuticals market. The large share of this region can be attributed to the increasing healthcare spending and the highly developed healthcare system in the US and Canada.
Request Sample [email protected]
The major players operating in this market are Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), LivaNova PLC (UK), Cochlear Ltd. (Australia), MicroPort Scientific Corporation (China), Sonova Group (Switzerland), Nevro Corp. (US), Axonics Modulation Technologies, Inc. (US), Neuronetics, Inc. (US), Second Sight Medical Products, Inc. (US), NeuroPace, Inc. (US), BIOTRONIK (Germany), Medico S.p.A. (Italy), Nurotron Biotechnology Co. Ltd. (US), MED-EL (Austria), Aleva Neurotherapeutics SA (Switzerland), NeuroSigma, Inc. (US), BioWave Corporation (US), Soterix Medical Inc. (US), Bioinduction Ltd. (UK), GiMer Medical (Taiwan), Cefaly (Belgium), BioControl Medical (Israel), and tVNS Technologies GmbH (Germany).